<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32686835</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>16</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>Motor neuron translatome reveals deregulation of SYNGR4 and PLEKHB1 in mutant TDP-43 amyotrophic lateral sclerosis models.</ArticleTitle><Pagination><StartPage>2647</StartPage><EndPage>2661</EndPage><MedlinePgn>2647-2661</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddaa140</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an incurable neurological disease with progressive loss of motor neuron (MN) function in the brain and spinal cord. Mutations in TARDBP, encoding the RNA-binding protein TDP-43, are one cause of ALS, and TDP-43 mislocalization in MNs is a key pathological feature of &gt;95% of ALS cases. While numerous studies support altered RNA regulation by TDP-43 as a major cause of disease, specific changes within MNs that trigger disease onset remain unclear. Here, we combined translating ribosome affinity purification (TRAP) with RNA sequencing to identify molecular changes in spinal MNs of TDP-43-driven ALS at motor symptom onset. By comparing the MN translatome of hTDP-43A315T mice to littermate controls and to mice expressing wild type hTDP-43, we identified hundreds of mRNAs that were selectively up- or downregulated in MNs. We validated the deregulated candidates Tex26, Syngr4, and Plekhb1 mRNAs in an independent TRAP experiment. Moreover, by quantitative immunostaining of spinal cord MNs, we found corresponding protein level changes for SYNGR4 and PLEKHB1. We also observed these changes in spinal MNs of an independent ALS mouse model caused by a different patient mutant allele of TDP-43, suggesting that they are general features of TDP-43-driven ALS. Thus, we identified SYNGR4 and PLEKHB1 to be deregulated in MNs at motor symptom onset in TDP-43-driven ALS models. This spatial and temporal pattern suggests that these proteins could be functionally important for driving the transition to the symptomatic phase of the disease.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Rita F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Neuronal Translational Control Research Group, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engler</LastName><ForeName>Jan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;chler</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuronal Translational Control Research Group, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Ross A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NGS-Integrative Genomics Core Unit (NIG), Institute of Human Genetics, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen 37077, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NGS-Integrative Genomics Core Unit (NIG), Institute of Human Genetics, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen 37077, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillingwater</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friese</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Kent E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Neuronal Translational Control Research Group, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485943">Plekhb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569019">SYNGR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062805">Synaptogyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062805" MajorTopicYN="N">Synaptogyrins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32686835</ArticleId><ArticleId IdType="pmc">PMC7530531</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddaa140</ArticleId><ArticleId IdType="pii">5868301</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland L.P. and Shneider N.A. (2001) Amyotrophic lateral sclerosis. N. Engl. J. Med., 344, 1688&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandan R. and Bradley W.G. (1985) Amyotrophic lateral sclerosis: part 1. Clinical features, pathology, and ethical issues in management. Ann. Neurol., 18, 271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">4051456</ArticleId></ArticleIdList></Reference><Reference><Citation>Stifani N. (2014) Motor neurons and the generation of spinal motor neuron diversity. Front. Cell. Neurosci., 8, 293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191298</ArticleId><ArticleId IdType="pubmed">25346659</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D. and Moore D.H. (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 14;2012(3):CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T. and Kiernan M.C. (2018) Riluzole, disease stage and survival in ALS. Lancet Neurol., 17, 385&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz M.P. (2018) Edaravone (Radicava): a novel Neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P. T., 43, 25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. (2019) Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev., 39, 733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C. and Petrucelli L. (2019) Genetic convergence brings clarity to the enigmatic red line in ALS. Neuron, 101, 1057&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hardiman O., Benatar M., Brooks B.R., Chio A., Carvalho M., Ince P.G., Lin C., Miller R.G., Mitsumoto H. &#xa0;et al. (2013) Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol., 12, 310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X. and Le W. (2013) Genetics of amyotrophic lateral sclerosis: an update. Mol. Neurodegener., 8, 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H. Jr. and Cleveland D.W. (2016) Decoding ALS: from genes to mechanism. Nature, 539, 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H. and Al-Chalabi A. (2017) Amyotrophic lateral sclerosis. N. Engl. J. Med, 377, 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce P.I., Fratta P., Fisher E.M. and Acevedo-Arozena A. (2011) SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome, 22, 420&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">21706386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H., Polymenidou M. and Cleveland D.W. (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol., 187, 761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Sun Y., Ling S.C., Ferraiuolo L., McAlonis-Downes M., Zou Y., Drenner K., Wang Y., Ditsworth D., Tokunaga S. &#xa0;et al. (2015) Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proc. Natl. Acad. Sci. USA, 112, E6993&#x2013;E7002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687558</ArticleId><ArticleId IdType="pubmed">26621731</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M. &#xa0;et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y. &#xa0;et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun., 351, 602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E. &#xa0;et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319, 1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M., Dion P.A. and Rouleau G.A. (2016) ALS: recent developments from genetics studies. Curr. Neurol. Neurosci. Rep., 16, 59.</Citation><ArticleIdList><ArticleId IdType="pubmed">27113253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F. &#xa0;et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 40, 572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Al-Chalabi A., Chio A., Hardiman O., Kiernan M.C., Rohrer J.D., Rowe J., Seeley W. and Talbot K. (2017) Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry, 88, 1042&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J. &#xa0;et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72, 245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Polymenidou M. and Cleveland D.W. (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron, 79, 416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Neumann M. and Mackenzie I.R. (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol., 8, 423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper L.J., Raaphorst J., Aronica E., Baas F., Haan R., Visser M. and Troost D. (2016) Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: a systematic neuropathological review. Neuropathol. Appl. Neurobiol., 42, 547&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">26373655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj A., Myers M.P., Buratti E. and Baralle F.E. (2013) Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res., 41, 5062&#x2013;5074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643599</ArticleId><ArticleId IdType="pubmed">23519609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.C., Sun E., Wancewicz E., Mazur C. &#xa0;et al. (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci., 14, 459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey J.R., Curk T., Rogelj B., Briese M., Cereda M., Kayikci M., Konig J., Hortobagyi T., Nishimura A.L., Zupunski V. &#xa0;et al. (2011) Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci., 14, 452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Lee V.M. and Trojanowski J.Q. (2011) TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med., 17, 659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Lagier-Tourenne C., Hutt K.R., Bennett C.F., Cleveland D.W. and Yeo G.W. (2012) Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res., 1462, 3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707312</ArticleId><ArticleId IdType="pubmed">22444279</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold E.S., Ling S.C., Huelga S.C., Lagier-Tourenne C., Polymenidou M., Ditsworth D., Kordasiewicz H.B., McAlonis-Downes M., Platoshyn O., Parone P.A. &#xa0;et al. (2013) ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA, 110, E736&#x2013;E745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Voigt A., Herholz D., Fiesel F.C., Kaur K., Muller D., Karsten P., Weber S.S., Kahle P.J., Marquardt T. and Schulz J.B. (2010) TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One, 5, e12247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923622</ArticleId><ArticleId IdType="pubmed">20806063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammer E.B., Fallini C., Gozal Y.M., Duong D.M., Rossoll W., Xu P., Lah J.J., Levey A.I., Peng J., Bassell G.J. &#xa0;et al. (2012) Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS One, 7, e38658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3380899</ArticleId><ArticleId IdType="pubmed">22761693</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana M.T., Piccinini M., Grifoni S., De Marco G., Vercellino M., Magistrello M., Pellerino A., Buccinna B., Lupino E. and Rinaudo M.T. (2010) TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol., 20, 351&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D. and Haass C. (2011) TDP-43 and FUS: a nuclear affair. Trends Neurosci., 34, 339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">21700347</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Tong J., Bi F., Zhou H. and Xia X.G. (2012) Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J. Clin. Invest., 122, 107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248298</ArticleId><ArticleId IdType="pubmed">22156203</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suarez-Farinas M., Schwarz C., Stephan D.A., Surmeier D.J. &#xa0;et al. (2008) A translational profiling approach for the molecular characterization of CNS cell types. Cell, 135, 738&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696821</ArticleId><ArticleId IdType="pubmed">19013281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M. and Baloh R.H. (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA, 106, 18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili M.A., Panahi M., Yadav S., Hennings L. and Kiaei M. (2013) Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int. J. Exp. Pathol., 94, 56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.I., Lee Y.D., Gwag B.J., Cho S.I., Kim S.S. and Suh-Kim H. (2008) Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J. Neurol. Sci., 268, 40&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">18054961</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A. and Henderson R.D. (2010) Effects of gender in amyotrophic lateral sclerosis. Gend. Med., 7, 557&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunham N.W. and Miya T.S. (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. Am. Pharm. Assoc., 46, 208&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">13502156</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T. and Rothstein J.D. (2015) Rodent models of amyotrophic lateral sclerosis. Curr. Protoc. Pharmacol., 69, 5.61.1&#x2013;5.67.21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.F., Gendron T.F., Zhang Y.J., Lin W.L., D'Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X. &#xa0;et al. (2010) Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci., 30, 10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Belfort G.M. and Kandror K.V. (2003) Cellugyrin and synaptogyrin facilitate targeting of synaptophysin to a ubiquitous synaptic vesicle-sized compartment in PC12 cells. J. Biol. Chem., 278, 47971&#x2013;47978.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928441</ArticleId></ArticleIdList></Reference><Reference><Citation>Valtorta F., Tarelli F.T., Campanati L., Villa A. and Greengard P. (1989) Synaptophysin and synapsin I as tools for the study of the exo-endocytotic cycle. Cell. Biol. Int. Rep., 13, 1023&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">2517595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q., Qi X., Zhang Y., Wu X., Liang M., Li C., Li D., Cardona C.J. and Xing Z. (2016) Synaptogyrin-2 promotes replication of a novel tick-borne Bunyavirus through interacting with viral nonstructural protein NSs. J. Biol. Chem., 291, 16138&#x2013;16149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4965563</ArticleId><ArticleId IdType="pubmed">27226560</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNair L., Xiao S., Miletic D., Ghani M., Julien J.P., Keith J., Zinman L., Rogaeva E. and Robertson J. (2016) MTHFSD and DDX58 are novel RNA-binding proteins abnormally regulated in amyotrophic lateral sclerosis. Brain, 139, 86&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">26525917</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandori C., Cowley S.M., James L.P. and Eisenman R.N. (2000) The Myc/max/mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol., 16, 653&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">11031250</ArticleId></ArticleIdList></Reference><Reference><Citation>Massari M.E. and Murre C. (2000) Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol. Cell. Biol., 20, 429&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85097</ArticleId><ArticleId IdType="pubmed">10611221</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes J., Wierda K., Snellinx A., Bounti L., Wang Y.C., Stancu I.C., Apostolo N., Gevaert K., Dewachter I., Spires-Jones T.L. &#xa0;et al. (2018) Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron, 97, 823&#x2013;835 &#xa0;e828.</Citation><ArticleIdList><ArticleId IdType="pubmed">29398363</ArticleId></ArticleIdList></Reference><Reference><Citation>Janz R. and Sudhof T.C. (1998) Cellugyrin, a novel ubiquitous form of synaptogyrin that is phosphorylated by pp60c-src. J. Biol. Chem., 273, 2851&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pubmed">9446595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupriyanova T.A. and Kandror K.V. (2000) Cellugyrin is a marker for a distinct population of intracellular Glut4-containing vesicles. J. Biol. Chem., 275, 36263&#x2013;36268.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou D., Pryor P.R., Gould G.W. and Bryant N.J. (2015) Alternative routes to the cell surface underpin insulin-regulated membrane trafficking of GLUT4. J. Cell Sci., 128, 2423&#x2013;2429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510850</ArticleId><ArticleId IdType="pubmed">26071524</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapel A., Kieffer-Jaquinod S., Sagne C., Verdon Q., Ivaldi C., Mellal M., Thirion J., Jadot M., Bruley C., Garin J. &#xa0;et al. (2013) An extended proteome map of the lysosomal membrane reveals novel potential transporters. Mol. Cell Proteomics, 12, 1572&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675815</ArticleId><ArticleId IdType="pubmed">23436907</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Ladak R., Swanson D.A., Soltyk A., Sun H., Ploder L., Vidgen D., Duncan A.M., Garami E., Valle D. &#xa0;et al. (1999) PHR1 encodes an abundant, pleckstrin homology domain-containing integral membrane protein in the photoreceptor outer segments. J. Biol. Chem., 274, 35676&#x2013;35685.</Citation><ArticleIdList><ArticleId IdType="pubmed">10585447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmon M.A. (2007) Pleckstrin homology (PH) domains and phosphoinositides. Biochem. Soc. Symp., 2007;(74):81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777418</ArticleId><ArticleId IdType="pubmed">17233582</ArticleId></ArticleIdList></Reference><Reference><Citation>Etournay R., El-Amraoui A., Bahloul A., Blanchard S., Roux I., Pezeron G., Michalski N., Daviet L., Hardelin J.P., Legrain P. &#xa0;et al. (2005) PHR1, an integral membrane protein of the inner ear sensory cells, directly interacts with myosin 1c and myosin VIIa. J. Cell Sci., 118, 2891&#x2013;2899.</Citation><ArticleIdList><ArticleId IdType="pubmed">15976448</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews K.L., Potdar P.D., Nettesheim P. and Ostrowski L.E. (2000) KPL1, which encodes a novel PH domain-containing protein, is induced during ciliated cell differentiation of rat tracheal epithelial cells. Exp. Lung Res., 26, 257&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10923244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhang Z., Wang H., Xia Y., Li X., Yan Y., Zou W., Zeng L. and Huang X. (2015) In vitro interaction between coxsackievirus B3 VP1 protein and human pleckstrin homology domain retinal protein (PHR1). Virus Genes, 51, 182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">26318175</ArticleId></ArticleIdList></Reference><Reference><Citation>Krappa R., Nguyen A., Burrola P., Deretic D. and Lemke G. (1999) Evectins: vesicular proteins that carry a pleckstrin homology domain and localize to post-Golgi membranes. Proc. Natl. Acad. Sci. USA, 96, 4633&#x2013;4638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16384</ArticleId><ArticleId IdType="pubmed">10200314</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Wang Y., Zhao H., Zhang L., Xiong W., Yau K.W., Hiel H., Glowatzki E., Ryugo D.K. and Valle D. (2004) PHR1, a PH domain-containing protein expressed in primary sensory neurons. Mol. Cell. Biol., 24, 9137&#x2013;9151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC517893</ArticleId><ArticleId IdType="pubmed">15456885</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S., Stauffer J.E., Schulte D.J. and Ravits J. (2015) Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol. Clin., 33, 855&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson P.T., Dickson D.W., Trojanowski J.Q., Jack C.R., Boyle P.A., Arfanakis K., Rademakers R., Alafuzoff I., Attems J., Brayne C. &#xa0;et al. (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 142, 1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner M., Menzies S. and Lutz Cathleen (2009) Working with ALS Mice: Guidelines for preclinical testing &amp; colony management. Prize4Life/Jackson Laboratory joint white paper.</Citation></Reference><Reference><Citation>Jones R.A., Harrison C., Eaton S.L., Llavero Hurtado M., Graham L.C., Alkhammash L., Oladiran O.A., Gale A., Lamont D.J., Simpson H. &#xa0;et al. (2017) Cellular and molecular anatomy of the human neuromuscular junction. Cell Rep., 21, 2348&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5723673</ArticleId><ArticleId IdType="pubmed">29186674</ArticleId></ArticleIdList></Reference><Reference><Citation>Aken B.L., Achuthan P., Akanni W., Amode M.R., Bernsdorff F., Bhai J., Billis K., Carvalho-Silva D., Cummins C., Clapham P. &#xa0;et al. (2017) Ensembl 2017. Nucleic Acids Res., 45, D635&#x2013;D642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210575</ArticleId><ArticleId IdType="pubmed">27899575</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M. and Gingeras T.R. (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Smyth G.K. and Shi W. (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30, 923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W. and Anders S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S., Spellman P.T., Birney E. and Huber W. (2009) Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomaRt. Nat. Protoc., 4, 1184&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159387</ArticleId><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Bardes E.E., Aronow B.J. and Jegga A.G. (2009) ToppGene suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res., 37, W305&#x2013;W311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703978</ArticleId><ArticleId IdType="pubmed">19465376</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico D., Isserlin R., Stueker O., Emili A. and Bader G.D. (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One, 5, e13984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2981572</ArticleId><ArticleId IdType="pubmed">21085593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>